Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 23:9:613307.
doi: 10.3389/fbioe.2021.613307. eCollection 2021.

Omics-Driven Biotechnology for Industrial Applications

Bashar Amer  1   2 , Edward E K Baidoo  1   2   3
Affiliations
Review

Omics-Driven Biotechnology for Industrial Applications

Bashar Amer et al. Front Bioeng Biotechnol. .

Abstract

Biomanufacturing is a key component of biotechnology that uses biological systems to produce bioproducts of commercial relevance, which are of great interest to the energy, material, pharmaceutical, food, and agriculture industries. Biotechnology-based approaches, such as synthetic biology and metabolic engineering are heavily reliant on "omics" driven systems biology to characterize and understand metabolic networks. Knowledge gained from systems biology experiments aid the development of synthetic biology tools and the advancement of metabolic engineering studies toward establishing robust industrial biomanufacturing platforms. In this review, we discuss recent advances in "omics" technologies, compare the pros and cons of the different "omics" technologies, and discuss the necessary requirements for carrying out multi-omics experiments. We highlight the influence of "omics" technologies on the production of biofuels and bioproducts by metabolic engineering. Finally, we discuss the application of "omics" technologies to agricultural and food biotechnology, and review the impact of "omics" on current COVID-19 research.

Keywords: biotechnology; genomics; metabolic engineering; metabolomics; multi-omics; proteomics; systems biology; transcriptomics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
An overview of the flow of molecular information from genes to metabolites to function and phenotype, and the interactions between the “omes” and the “omics” techniques used to measure them.
Figure 2
Figure 2
“Omics” approaches facilitate the development of new biotechnologies.
Figure 3
Figure 3
The Design-Build-Test-Learn (DBTL) cycle of metabolic engineering.
Figure 4
Figure 4
Number of annual publications that utilize “omics” technologies for biotechnology during the period of 2000–2020. Search criteria: the individual “omics” technology was selected. The search was conducted using the Web of Science platform.
Figure 5
Figure 5
Number of annual publications that utilize “omics” technologies for biotechnology research areas during the period of 2000–2020. Search criteria: the individual “omics” technology and the individual biotechnology research area were selected. The search was conducted using the Web of Science platform.
See this image and copyright information in PMC

References

    1. Abid F., Zahid M. A., Abedin Z. U., Nizami S. B., Abid M. J., Kazmi S. Z. H., et al. . (2018). Omics Approaches in Marine Biotechnology: The Treasure of Ocean for Human Betterments. London: Elsevier Inc.
    1. Ahmed Z., Zeeshan S., Foran D. J., Kleinman L. C., Wondisford F. E., Dong X. Q. (2020). Integrative clinical, genomics and metabolomics data analysis for mainstream precision medicine to investigate COVID-19. BMJ Innov. 7, 1–5. 10.1136/bmjinnov-2020-000444 - DOI
    1. Aichler M., Walch A. (2015). MALDI imaging mass spectrometry: current frontiers and perspectives in pathology research and practice. Lab. Investig. 95, 422–431. 10.1038/labinvest.2014.156 - DOI - PubMed
    1. Aizat W. M., Ismail I., Noor N. M. (2018). Recent development in omics studies, in Advances in Experimental Medicine and Biology, eds Aizat W. M., Goh H-H., Baharum S. N. (New York, NY: Springer New York LLC; ), 1–9. 10.1007/978-3-319-98758-3_1 - DOI - PubMed
    1. Alfaro M. P., Sepulveda J. L., Lyon E. (2019). Molecular testing for targeted therapies and pharmacogenomics, in Accurate Results in the Clinical Laboratory, eds Dasgupta A., Sepulveda J. L. (Amsterdam: Elsevier; ), 349–363. 10.1016/b978-0-12-813776-5.00022-4 - DOI